Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Management of adjuvant/neoadjuvant HCC in 2024 

How are locoregional therapies evolving in HCC?

Date

16 Sep 2024

Session

Management of adjuvant/neoadjuvant HCC in 2024 

Topics

Immunotherapy;  Surgical Oncology

Tumour Site

Hepatobiliary Cancers

Presenters

Bruno Sangro

Authors

B. Sangro

Author affiliations

  • Liver Unit, Clinica Universidad de Navarra, 31008 - Pamplona/ES

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.